---
title: "Adagio Medical Announces Positive Pivotal FULCRUM-VT Results; 84% Shock-Free at 6 Months"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284193943.md"
description: "Adagio Medical announced positive results from its FULCRUM-VT pivotal IDE trial, reporting 84% freedom from ICD shock and 59% freedom from VT recurrence at 6 months. Key highlights include 98% non-inducibility of targeted VTs post-procedure, a 2.4% major adverse event rate, and a 1.9% 30-day VT-related readmission rate, indicating a favorable safety profile. The outcomes were consistent across ischemic and non-ischemic cardiomyopathy patients, with over 72% of patients reducing or discontinuing amiodarone and an 80% reduction in ICD shocks post-ablation."
datetime: "2026-04-27T10:13:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284193943.md)
  - [en](https://longbridge.com/en/news/284193943.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284193943.md)
---

# Adagio Medical Announces Positive Pivotal FULCRUM-VT Results; 84% Shock-Free at 6 Months

**Adagio Medical reported 84% freedom from ICD shock and 59% freedom from VT recurrence at 6 months in the FULCRUM-VT pivotal IDE trial.**

**Key Highlights:**

-   98% non-inducibility of targeted VTs at end of procedure, indicating strong acute procedural effectiveness.
-   84% freedom from ICD shock and 59% freedom from any VT recurrence at 6 months, supporting clinical benefit.
-   2.4% protocol-defined major adverse event rate and 1.9% 30-day VT-related readmission, indicating a favorable safety profile.
-   Equivalent outcomes for ischemic and non-ischemic cardiomyopathy patients, first endocardial tech to show parity across substrates.
-   72% of patients discontinued or reduced amiodarone and \>80% reduction in patients experiencing ICD shock versus pre-ablation.

Original SEC Filing: Adagio Medical Holdings, Inc. \[ ADGM \] - 8-K - Apr. 27, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ADGM.US](https://longbridge.com/en/quote/ADGM.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress | ADGM Stock News](https://longbridge.com/en/news/286095782.md)
- [Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/286893528.md)
- [Resona Asset Management Co. Ltd. Cuts Position in Danaher Corporation $DHR](https://longbridge.com/en/news/286897088.md)
- [Edwards Lifesciences CVP, Strategy/Corp Development Sold Shares Worth Over $1.4M](https://longbridge.com/en/news/286822028.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)